PURPOSE: Current assessment of lymph node metastasis in patients with head and neck squamous cell carcinoma is not accurate enough to prevent overtreatment. The aim of this study was validation of a gene expression signature for distinguishing metastasizing (N+) from nonmetastasizing (N0) squamous cell carcinoma of the oral cavity (OSCC) and oropharynx (OPSCC) in a large multicenter cohort, using a diagnostic DNA microarray in a Clinical Laboratory Improvement Amendments/International Organization for Standardization-approved laboratory. METHODS: A multigene signature, previously reported as predictive for the presence of lymph node metastases in OSCC and OPSCC, was first re-evaluated and trained on 94 samples using generic, whole-genome, DNA microarrays. Signature genes were then transferred to a dedicated diagnostic microarray using the same technology platform. Additional samples (n=222) were collected from all head and neck oncologic centers in the Netherlands and analyzed with the diagnostic microarray. Human papillomavirus status was determined by real-time quantitative polymerase chain reaction. RESULTS: The negative predictive value (NPV) of the diagnostic signature on the entire validation cohort (n=222) was 72%. The signature performed well on the most relevant subset of early-stage (cT1-T2N0) OSCC (n=101), with an NPV of 89%. CONCLUSION: Combining current clinical assessment with the expression signature would decrease the rate of undetected nodal metastases from 28% to 11% in early-stage OSCC. This should be sufficient to enable clinicians to refrain from elective neck treatment. A new clinical decision model that incorporates the expression signature is therefore proposed for testing in a prospective study, which could substantially improve treatment for this group of patients.
PURPOSE: Current assessment of lymph node metastasis in patients with head and neck squamous cell carcinoma is not accurate enough to prevent overtreatment. The aim of this study was validation of a gene expression signature for distinguishing metastasizing (N+) from nonmetastasizing (N0) squamous cell carcinoma of the oral cavity (OSCC) and oropharynx (OPSCC) in a large multicenter cohort, using a diagnostic DNA microarray in a Clinical Laboratory Improvement Amendments/International Organization for Standardization-approved laboratory. METHODS: A multigene signature, previously reported as predictive for the presence of lymph node metastases in OSCC and OPSCC, was first re-evaluated and trained on 94 samples using generic, whole-genome, DNA microarrays. Signature genes were then transferred to a dedicated diagnostic microarray using the same technology platform. Additional samples (n=222) were collected from all head and neck oncologic centers in the Netherlands and analyzed with the diagnostic microarray. Human papillomavirus status was determined by real-time quantitative polymerase chain reaction. RESULTS: The negative predictive value (NPV) of the diagnostic signature on the entire validation cohort (n=222) was 72%. The signature performed well on the most relevant subset of early-stage (cT1-T2N0) OSCC (n=101), with an NPV of 89%. CONCLUSION: Combining current clinical assessment with the expression signature would decrease the rate of undetected nodal metastases from 28% to 11% in early-stage OSCC. This should be sufficient to enable clinicians to refrain from elective neck treatment. A new clinical decision model that incorporates the expression signature is therefore proposed for testing in a prospective study, which could substantially improve treatment for this group of patients.
Authors: Christina Bluemel; Domenico Rubello; Patrick M Colletti; Remco de Bree; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2015-04-28 Impact factor: 9.236
Authors: Matthew L Hedberg; Gerald Goh; Simion I Chiosea; Julie E Bauman; Maria L Freilino; Yan Zeng; Lin Wang; Brenda B Diergaarde; William E Gooding; Vivian W Y Lui; Roy S Herbst; Richard P Lifton; Jennifer R Grandis Journal: J Clin Invest Date: 2015-11-30 Impact factor: 14.808
Authors: L J Melchers; M J A M Clausen; M F Mastik; L Slagter-Menkema; J E van der Wal; G B A Wisman; J L N Roodenburg; E Schuuring Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-03-07 Impact factor: 2.503
Authors: Michael D Onken; Ashley E Winkler; Krishna-Latha Kanchi; Varun Chalivendra; Jonathan H Law; Charles G Rickert; Dorina Kallogjeri; Nancy P Judd; Gavin P Dunn; Jay F Piccirillo; James S Lewis; Elaine R Mardis; Ravindra Uppaluri Journal: Clin Cancer Res Date: 2014-03-25 Impact factor: 12.531
Authors: Chi T Viet; Gary Yu; Kesava Asam; Carissa M Thomas; Angela J Yoon; Yan Chen Wongworawat; Mina Haghighiabyaneh; Courtney A Kilkuts; Caitlyn M McGue; Marcus A Couey; Nicholas F Callahan; Coleen Doan; Paul C Walker; Khanh Nguyen; Stephanie C Kidd; Steve C Lee; Anupama Grandhi; Allen C Cheng; Ashish A Patel; Elizabeth Philipone; Olivia L Ricks; Clint T Allen; Bradley E Aouizerat Journal: Biomark Res Date: 2021-06-05